addition, the Immediate Office is also responsible for data gathering, analysis, and dissemination; preparation of reports; budget projection, planning, execution and tracking; research development and communication of findings; and identification and utilization of new technology in managing the Bureau's workload and communicating with the Department, Regional Office, States, Territories, Tribes and the child care field. The Immediate Office also supports the unique program and planning needs of tribal grantees.

2. The Program Operations Division is responsible for Regional Liaison activities, including: communication on a regular basis with Regional Office staff; responding to questions on policy and other issues by consulting or referring to other staff; tracking progress of grantee programs in coordination with the Regions; collecting and maintaining information related to grantee program implementation, administrative data, technical assistance data, and technical assistance efforts; tracking program achievements, problems, and gaps; identifying latest trends and activities of major significance; preparing background material, fact sheets, and articles to provide information to Regional Offices, grantees and the general public; and tracking and supporting special initiatives. This unit also establishes partnerships with public and private entities to improve access to quality child care; coordinate program activities with other government and non-government agencies; and manages and oversees the Bureau's cooperative ventures with other entities.

3. The Policy Division develops, interprets and issues national policies and regulations governing Child Care and Development Fund (CCDF) programs. The Policy Division provides clarification of the statutes, regulations and policies; issues action transmittals and information memoranda; recommends and drafts legislative proposals; prepares briefing materials for hearings and testimony; updates the child care plan preprints; reviews and gives guidance to Regional Offices on CCDF plans and applications; oversees a data base of grantee plans; researches child care policy issues; coordinates policies and procedures with other Federal agencies; provides policy training, guidance and clarification to Regional Offices in carrying out policy functions; and manages controlled correspondence.

4. The Technical Assistance Division provides technical assistance to Regional Offices, States, Territories, and Tribes concerning CCDF in order to make affordable quality child care accessible to families. It provides leadership, coordination and contract management for technical assistance projects that comprise the Child Care Technical Assistance Network. This unit also oversees and supports national conferences, leadership forums, and Regional Office conferences. It oversees the development of technical assistance materials including publications.

Dated: October 20, 1998.

James Harrell,

Deputy Commissioner, Administration on Children, Youth and Families.

[FR Doc. 98–29191 Filed 10–30–98; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. 98F–0593, 98F–0674, and 98F–0707]

Dover Chemical Corp.; Withdrawal of Food Additive Petitions

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of food additive petitions (FAP's 8B4614, 8B4613, and 8B4621) proposing that the food additive regulations be amended to provide for the safe use of 3,9-bis[2,4-bis(1-methyl-1-phenylethyl)phenoxy]-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecane, which may contain not more than 2 percent by weight of triisopropanolamine, as an antioxidant and/or stabilizer for polymers (specifically, polyetherimide resins), olefin polymers, or polycarbonate and polyethylene phthalate polymers intended for use in contact with food.

FOR FURTHER INFORMATION CONTACT: Vir D. Anand, Center for Food Safety and Applied Nutrition (HFS–215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3081.

SUPPLEMENTARY INFORMATION: In notices published in the **Federal Registers** of July 30, 1998 (63 FR 40720), August 19, 1998 (63 FR 44463), and August 25, 1998 (63 FR 45248), FDA announced that food additive petitions (FAP's 8B4614, 8B4613, and 8B4621) had been filed by Dover Chemical Corp., 3676 Davis Rd. NW., Dover, OH 44622. The petitions proposed to amend the food additive regulations in § 178.2010 *Antioxidants and/or stabilizers for polymers* (21 CFR 178.2010) to provide for the safe use of 3,9-bis[2,4-bis(1-methyl-1-phenyethyl)phenoxy]-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecane, which may contain not more than 2 percent by weight of triisopropanolamine, as an antioxidant and/or stabilizer for polymers (specifically, polyetherimide resins), olefin polymers, or polycarbonate and polyethylene phthalate polymers intended for use in contact with food. Dover Chemical Corp. has now withdrawn the petitions (FAP's 8B4614, 8B4613, and 8B4621) without prejudice to a future filing (21 CFR 171.7).

Dated: October 16, 1998.

Laura M. Tarantino,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 98–29188 Filed 10–30–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Center for Biologics Evaluation and Research Medical Device Action Plan; Public Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of meeting.

The Food and Drug Administration (FDA) is announcing the following meeting: Center for Biologics Evaluation and Research Medical Device Action Plan. FDA is inviting interested parties, including industry, health professionals, patients and their advocacy groups to present their suggestions for improvements to the Center for Biologics Evaluation and Research's (CBER's) regulation of medical devices, or reasons to maintain the current systems to protect public health.

Date and Time: The meeting will be held on Tuesday, December 1, 1998, 9 a.m. to 5 p.m.

Location: The meeting will be held at Natcher Auditorium, Balcony B, National Institutes of Health, 8800 Rockville Pike, Bethesda, MD.

Contact: Kathy A. Eberhart, Center for Biologics Evaluation and Research (HFM–43), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–827–1317, FAX 301–827–3079, e-mail ''Eberhart@CBER.FDA.GOV''.